Epidermal growth factor receptor (EGFR) × mesenchymal–epithelial transition factor (MET)‐targeting BsAb amivantamab, functions via blocking ligand‐induced activation and leads to internalization and degradation of Ab‐bound receptors, thereby inhibiting tumour cell proliferation. The gene discussed is EGFR; the disease is neoplasm.